Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University

Meena Bansal, MD, is director of the MASLD/MASH (NAFLD/NASH) Center of Excellence at Mount Sinai and System Chief, Division of Liver Diseases for the Mount Sinai Health System.

Are We Screening Women for MASLD Often Enough?

metabolic dysfunction-associated steatotic liver disease (MASLD)

 continues to rise, clinicians are increasingly questioning whether current screening approaches fully capture risk in women. While existing guidelines identify key metabolic risk factors, concerns exist regarding their ability to adequately account for the physiologic changes women experience across the lifespan, particularly during transitions like menopause and pregnancy that significantly influence disease progression.

Current MASLD screening guidelines effectively identify at-risk populations but may not fully account for sex-specific risk across a woman’s lifespan.

The interval of monitoring is important, especially during high-risk transitions such as menopause, when fibrosis progression may accelerate.

Women with metabolic risk factors and early fibrosis may benefit from more frequent noninvasive assessments rather than standard multi-year follow-up.

PCOS screening and recognition should be part of risk assessment in younger women, given its link to insulin resistance and MASLD.

Greater engagement of OB/GYN providers is needed, as they often serve as primary care providers and are well-positioned to identify at-risk patients.

Patient empowerment is essential, including encouraging women to understand their risk, calculate FIB-4 scores, and advocate for further evaluation when steatosis is identified.

Liver Lineup: Updates and Unfiltered Insights

, Meena Bansal, MD, joins Nancy Reau, MD, and Kimberly Brown, MD, to examine a critical but often overlooked question in hepatology: should screening strategies for MASLD differ for women?

The discussion begins with Brown raising the possibility that while current guidelines effectively identify at-risk populations like individuals with diabetes, insulin resistance, or metabolic syndrome, they may not fully account for key transitions in a woman’s life. Bansal agrees that existing frameworks are generally sound but emphasizes that timing and frequency of screening are where clinicians may need to adapt their approach.

Rather than redefining who should be screened, Bansal highlights the importance of adjusting monitoring intervals during periods of increased risk, particularly around menopause. As hormonal changes accelerate metabolic dysfunction and fibrosis progression, she suggests that women in this transition, especially those with additional risk factors like diabetes or early fibrosis, may benefit from more frequent noninvasive assessments. Tools such as vibration-controlled transient elastography or serum-based biomarkers can help identify disease progression earlier, creating an opportunity for timely intervention.

Reau reinforces this point with clinical experience, noting that some patients previously considered low risk can return years later with advanced disease, often after significant metabolic changes and menopause, underscoring the need for greater vigilance during these inflection points.

Beyond hepatology, the conversation further expands to the role of multidisciplinary care. Bansal stresses the importance of engaging obstetricians and gynecologists, who often serve as primary care providers for many women. While awareness is growing, she notes that more education is needed to ensure these clinicians incorporate liver disease screening into routine care for at-risk patients. This includes using simple tools like the FIB-4 index as an initial step, followed by additional testing when indicated.

The group also highlights the importance of patient empowerment. Women are frequently told that “fatty liver” is benign, which may delay further evaluation. Encouraging patients to understand their risk factors, calculate their own FIB-4 scores, and advocate for follow-up care can play a meaningful role in earlier detection.

Editors’ note: Relevant disclosures for 

 include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for 

 include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for 

 include Boeheringer-Ingelheim, Boston Pharma, Fibronostics, GSK, Madrigal, Merck, NOVO Nordisk, and The Kinetix Group.

DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology. 2020;161(10):bqaa134. doi:10.1210/endocr/bqaa134

Sarkar M, Kushner T. Metabolic dysfunction-associated steatotic liver disease and pregnancy. J Clin Invest. 2025;135(10):e186426. Published 2025 May 15. doi:10.1172/JCI186426

Mass General Brigham. Patients Who Discontinued GLP-1s Had More Weight Gain, Complications During Pregnancy. November 24, 2025. Accessed April 20, 2026. 

https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/pregnancy-effects-from-discontinued-glp-1-use

Videos

Experts call for greater awareness, improved collaboration with OB/GYNs, and more proactive MASLD screening strategies for women.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Screening Smarter: Identifying MASLD Risk in Women

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

Asundexian Reduces Stroke Incidence Without Increasing Bleeding, With Ashkan Shoamanesh, MD

Asundexian, an investigational Factor XIa inhibitor, lowers the risk of stroke in patients who recently experienced non-cardioembolic 

 or a transient ischemic attack (TIA) without increasing bleeding, according to data from OCEANIC-STROKE.

Despite secondary prevention strategies, 5.1% of patients with ischemic stroke or TIA have a recurrent stroke within 1 year – after 5 years, 22% of patients who had survived the event are disabled or dead. Dual antiplatelet therapy incompletely reduces this risk, and long-term use is associated with higher risks of major hemorrhage. FXIa inhibition approaches the condition from a new angle, potentially circumventing these issues.

“Not only are we not seeing excess in major bleeding, but we also didn’t see excess in minor bleeding,” Ashkan Shoamanesh, MD, associate professor of medicine and Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, told 

 in an exclusive interview. “Although minor bleeding is a less immediate clinical consequence regarding health, it certainly still is very significant, because it results in substantial psychological distress for patients and leads to non-compliance, which leads to less efficacy. It’s frankly historic to have a trial of this size and to have confidence in the results, and to see no excess risk with an antithrombotic versus placebo.”

OCEANIC-STROKE was a phase 3, double-blind, event-driven, randomized, placebo-controlled trial conducted at 702 centers across 37 countries. Patients were eligible if they were ≥18 years old with a non-cardioembolic ischemic stroke or high-risk TIA within 72 hours after the onset of symptoms and had a plan for treatment with dual or single antiplatelet therapy. Those with a history of atrial fibrillation or other conditions with an indication for anticoagulation, active nontrivial bleeding, or a qualifying stroke related to a procedure or other specific cause were excluded.

After enrollment, patients were randomly assigned in a 1:1 ratio to either asundexian 50 mg daily or matching placebo, on top of planned dual or single antiplatelet therapy. The trial’s primary outcome was the first occurrence of ischemic stroke, which was determined to have occurred if there was a new focal neurologic deficit or clinically meaningful worsening of an existing deficit persisting for ≥24 hours. The primary safety outcome was major bleeding, including fatal bleeding, symptomatic bleeding in a critical area or organ, and clinically overt bleeding resulting in a hemoglobin reduction of ≥2 g/dL.

A total of 12,327 patients were randomized, with 6162 assigned to the asundexian group and 6165 to placebo. A total of 45 patients withdrew consent, and 39 were lost to follow-up. The mean age of the final group of patients was 68 years. 11,677 patients presented with ischemic stroke, while the remainder had TIA. Median follow-up was 567 days (interquartile range [IQR], 377-729).

Ultimately, Shoamanesh and colleagues found that ischemic stroke incidence was substantially lower in the asundexian group than the placebo group (6.2% vs 8.4%; cause-specific HR, 0.74; 95% CI, 0.65-0.84; 

 <.001). The incidence of a composite of death from cardiovascular causes, myocardial infarction, or stroke was also lower in the asundexian arm. Major bleeding incidence was similar between both arms (1.9% and 1.7%, respectively; cause-specific HR, 1.1; 95% CI, 0.85-1.44). Adverse events occurred in 69.3% of the asundexian group and 70.1% in the placebo group – serious adverse events had an incidence of 19.2% and 19.5%, respectively.

The team concluded that treatment with asundexian substantially reduced the risk of ischemic stroke and major cardiovascular events compared with placebo, without increasing the risk of major bleeding in patients. Shoamanesh and colleagues believe that these data mark the beginning of a major shift in ischemic stroke treatment, and in cardiovascular disease overall, as a result of FXIa inhibition’s success.


“I think this is just the beginning of a large paradigm shift in our treatment of patients with cardiovascular disease,” Shoamanesh said. “Certainly, to date, there have been challenges with factor XI and other disease states. But I suspect the reason for that is that we just haven’t found the right recipe yet – either with higher doses of existing agents or with combination treatments, factor XI is going to be used more widely across the spectrum of cardiovascular disease and venous thromboembolic disease.”

Editors’ Note: Shoamanesh reports disclosures with the Heart and Stroke Foundation of Canada, the Marta and Owen Boris Foundation, Bayer AG, Daiichi Sankyo, AstraZeneca, Octapharma, Inc., and others.

McMaster University. New anti-clotting medication lowers risk of stroke without added bleeding. 

. April 15, 2026. Accessed April 20, 2026. 

https://www.eurekalert.org/news-releases/1123838

Sharma M, Dong Q, Hirano T, et al. Asundexian for secondary stroke prevention. 

Shoamanesh discusses the positive data from OCEANIC-STROKE, a phase 3 trial comparing the investigative FXIa inhibitor to placebo in patients with prior ischemic stroke.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Marie-José van Tol, PhD, from the University of Groningen.

Targeting Positive Affect May Prevent Depression Relapse, With Marie-José van Tol, PhD

New data suggest preventive cognitive therapy (PCT) may reduce relapse risk in recurrent 

by strengthening positive affect and modifying dysfunctional beliefs. In an interview with 

Marie-José van Tol, PhD, from the University of Groningen, described practical techniques clinicians can incorporate to enhance resilience during remission and potentially lower recurrence risk.

One strategy emphasized in PCT is “positive fantasizing,” a structured exercise designed to challenge rigid negative self-beliefs. Patients first identify a maladaptive belief, such as “I must do everything right to be worthwhile,” and then deliberately invert it.

“When you…think ‘I have to do everything right in order to be worthwhile,’ so making a mistake makes me [a] worthless person, we invited them to think…even if I do everything wrong, people will still find me fantastic,” van Tol said. “They were invited to think of their dream world, where they would live according to this fantasy belief, and that makes them experience that if they would think differently about themselves, they would feel different. They would have a different posture, they would say different things, they [might] make different jokes. So, it is [both] a positive effect enhancer, but it also invites people to understand the link between what they think and how they feel and experience that maybe there is some room, and their rigid negative belief might be shifted a bit towards a more helpful content.”

Van Tol suggested clinicians encourage patients to track events that went well, note moments of enjoyment, and “savor” small pleasurable experiences. Maintaining a positivity diary may help individuals recovering from depression re-engage with reward processing and rebuild comfort with positive emotions, which can diminish during depressive episodes. These practices aim to strengthen consummatory pleasure and support adaptive cognitive reappraisal

Although the findings are based on a relatively small and selective sample, van Tol noted that stability analyses, including bootstrapping approaches, supported the robustness of the observed associations. She emphasized that larger studies are needed to confirm generalizability and clarify causal relationships, particularly through more frequent longitudinal sampling of beliefs and affective states. Future research will also examine whether specific interventions, such as positive fantasizing, translate into sustained reductions in relapse risk.

“It's very important to realize that there is we focus often on the negative, effective domain in depression, but…there is [another] important domain,” she said. “I think that's good news, and I think it's very important to realize that even after a depression, we can help people build up resilience through offering certain therapy.”

Watch part 1 of the interview with van Tol here: 

Preventive Therapy Targeting Positive Affect May Reduce MDD Relapse, With Marie-José van Tol, PhD

Angeles-Valdez D, van Kleef R, van Valen E, Garza-Villarreal EA, Bockting C, van Tol MJ. The role of cognitive and affective changes in preventing depressive relapse: A network analysis approach to understanding the mechanisms of preventive cognitive therapy. 

Preventive cognitive therapy may reduce relapse in recurrent depression by strengthening positive affect and addressing anhedonia, van Tol explained.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Rezpegaldesleukin (REZPEG) therapy may lead to continued improvements in hair regrowth and Severity of Alopecia Tool (SALT) scores through 52 weeks among individuals with 

These findings, announced on April 20 by Nektar Therapeutics, represent the updated results of a blinded 16-week extension of the phase 2b REZOLVE-AA study assessing rezpegaldesleukin, an investigational interleukin (IL)-2 pathway agonist designed to selectively expand regulatory T cells, in patients with severe-to-very-severe alopecia areata, or hair loss.

“The new SALT≤20 responders in this set of patients treated out to 52 weeks reflect how the T regulatory cell mechanism of REZPEG can have more clinical benefit over time, a phenomenon the investigators observed in the Phase 2 study in atopic dermatitis as well," Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at The George Washington University School of Medicine and Health Sciences, said in a statement.

92 patients who had been naïve to prior Janus-kinase (JAK) inhibitors or biologic drugs were involved in this global study, with trial investigators randomizing them during a 36-week induction period to be given either 1 of 2 dose regimens of rezpegaldesleukin or placebo. These regimens were administered as twice-monthly subcutaneous injections. Overall, the investigators identified notable baseline disease burden, with mean SALT scores being near 78 in the treatment cohorts and 76.6 in the placebo cohort.

Additionally, there had been a median disease duration of approximately 6 - 7 years. After the study’s induction phase, those who demonstrated some hair regrowth but continued to have significant scalp involvement (SALT >20) were deemed eligible to jin a blinded extension period through Week 52. There were 31 total patients who continued into this phase, including 27 on a rezpegaldesleukin regimen, with a low- (18 µg/kg; n = 14) and high-dose (24 µg/kg; n = 13) cohort. There were 4 remaining on placebo.

In REZOLVE-AA’s extension period, additional clinical responses were observed, with 29% of individuals featured in the low-dose arm and 31% in the high-dose arm attaining new SALT ≤20 responses. This corresponded to ≥80% scalp hair coverage. This was compared with no new responders in the placebo arm of the trial. By the 52-week mark, outcomes across the overall study population continued to favor rezpegaldesleukin therapy.

The proportion of participants with a SALT ≤20 score rose to 25.8% in the low-dose cohort and 27.6% in the high-dose cohort, with only 6.7% in the placebo arm (

 = .049). In a similar finding, the investigative team observed rates of SALT ≤30, representing ≥70% scalp hair coverage, attained by 30.2% and 35.0% of those in the low- and high-dose groups, respectively, versus 8.4% with placebo (

In the team’s additional efficacy endpoints, findings also demonstrated improvements with active treatment. Such results included SALT50 responses observed in 37.7% and 38.8% of individuals in the low- and high-dose arms, respectively. This was compared with only 13.6% noted among those in the placebo arm. SALT30 responses were seen in 45.6% and 47.6% of participants treated with rezpegaldesleukin, versus 24.2% with placebo.

Collectively, these data were described by Nektar as indicators that continued rezpegaldesleukin use may lead to incremental improvements in hair regrowth over time in those living with severe alopecia areata. The company further noted its plans for the REZOLVE-AA results to be submitted for presentation at a medical meeting in 2026.

"Given the prescribing and safety limitations of JAK inhibitors, these new data point to the potential for rezpegaldesleukin to be the first safe and effective biologic in alopecia areata, which may completely transform the management of the disease,” Silverberg said in his statement.

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin. Nektar Therapeutics. April 20, 2026. 

https://www.prnewswire.com/news-releases/52-week-topline-results-from-16-week-blinded-treatment-extension-of-rezolve-aa-demonstrate-deepening-of-responses-in-severe-to-very-severe-alopecia-areata-with-rezpegaldesleukin-302746837.html

Chovatiya R. REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD. HCPLive. March 20, 2026. Accessed April 20, 2026. 

https://www.hcplive.com/view/rezolve-ad-rezpegaldesleukin-consistent-efficacy-across-atopic-dermatitis-severity-chovatiya

Articles

Rezpegaldesleukin, an investigational IL-2 pathway agonist intended to selectively expand regulatory T cells, demonstrated deepening clinical activity through 52 weeks in severe-to-very-severe alopecia areata. In a phase 2b global population naïve to prior JAK inhibitors/biologics, baseline SALT scores were ~77 with median disease duration 6–7 years. Among extension-eligible participants with residual SALT >20 after induction, additional new SALT ≤20 responses emerged with both 18 and 24 µg/kg dosing, while placebo showed none.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

Maria Hordinsky, MD, is an R.W. Goltz Professor of the Department of Dermatology at the University of Minnesota.

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD

Cosmo Pharmaceuticals announced positive 12-month phase 3 findings on clascoterone 5% topical solution in men with 

mild-to-moderate androgenetic alopecia (AGA)

, noting the treatment’s sustained efficacy with continued use.

These data highlighting the success of the drug in recent phase 3 clinical trials were discussed by trial investigator Maria Hordinsky, MD, an R.W. Goltz professor of dermatology at the University of Minnesota, who emphasized the significance of the results from both clinical and patient perspectives. The trial program was described as the largest phase 3 program ever done for a topical treatment of androgenetic alopecia in males, with 1465 patients recruited across 51 sites in US and Europe.

“There hasn't been a new FDA…medical treatment, for over 30 years,” Hordinsky noted. “It's been a long time since something has come to this point with with the current medication. We now have the opportunity to really use a topical agent that targets the androgen receptor, one of the key players in androgenetic alopecia.”

In Hordinsky’s view, this positions clascoterone as a potentially important addition to the treatment armamentarium. As a topical androgen receptor inhibitor, the therapy directly targets a key driver of AGA, providing a novel mechanism of action compared to existing choices among patients suffering from such hair loss conditions. She highlighted the clinical relevance of the sustained efficacy observed between Months 6 - 12, describing the continued improvement over time as exciting.

Although she expressed interest in seeing longer-term durability data in real-world settings, Hordinsky underscored these 12-month findings, already, show meaningful persistence of benefit for those with AGA. With regard to the reported 239% relative improvement in target area hair count (TAHC), she stressed while numerical metrics are important, perception among patients also remains central. Hair counts rising can translate into visible, tangible shifts for those with hair loss, aligning clinical outcomes with real-world expectations of improved hair appearance and density.

The trial design, which involved a comparison between subjects on clascoterone and those shifted to vehicle following 6 months, additionally reinforced the value of ongoing use. Those who discontinued active treatment reported a gradual loss of benefit, suggesting consistent use may be necessary to maintain the positive results. Looking ahead, Hordinsky noted clascoterone would likely fit well into a growing and increasingly personalized AGA treatment landscape.

For more information on these data, view the full video interview posted above.

Hordinsky has served on an advisory board for AbbVie (fees) and as an investigator receiving grants or research funding from Arcutis Biotherapeutics, Cassiopea, Concert Pharmaceuticals, Eli Lilly and Company, National Alopecia Areata Foundation, RegenLab, and Sun Pharmaceuticals. She has also received fees for other work with UpToDate, Inc.

Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which Are Statistically Significant. Cosmo Pharmaceuticals. April 15, 2026. Accessed April 20, 2026. 

https://www.cosmohealthconfidence.com/news/98958067-clascoterone-12-month-safety-results-ende

Hordinsky M. Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD. HCPLive. December 18, 2025. Accessed April 20, 2026. 

https://www.hcplive.com/view/phase-3-scalp-study-clascoterone-androgenetic-alopecia-maria-hordinsky-md

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Phase 3 MIRANDA found tozorakimab reduced COPD exacerbations in former smokers despite inhaled maintenance therapy.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Phase 3 MIRANDA Trial Links Tozorakimab to Fewer COPD Exacerbations

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Phase 3 HIBISCUS: Etavopivat Cuts VOC Events, Improves Hemoglobin in SCD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

In the final episode, "Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions," the panelists explore how the full body of available evidence, including comparative analyses, long term extension studies, real world data, and clinical experience, can be integrated into practical treatment decision making for plaque psoriasis.

Video Series

Integrating Comparative Evidence to Optimize Psoriasis Treatment Decisions

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Aliza Narva, JD, discusses how clinical ethics consultation works in practice, from bedside dilemmas to mediation-based approaches and clinician support.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Medical Ethics Unpacked

Medical Ethics Unpacked is a regular multimedia series hosted by Dominic Sisti, PhD, and Steve Levine, MD, spotlighting a spectrum of topics within the field of medical ethics. Throughout the year, hosts will sit down for an in-depth discussion on a specific ethical dilemma within modern healthcare, with some episodes also featuring a special guest. 

Check back throughout the year for discussions on a variety of topics, including data privacy in health apps, euthanasia and medical assistance in dying, reproductive rights and technologies, and more!

Medical Ethics Unpacked: Clinical Ethics Consultation in Practice

In this episode, "Evaluating IL-23 Inhibitors with Long-Term Data and Real-World Evidence," the expert dermatologists explore the distinct but complementary roles of long term extension studies and real world evidence in evaluating the durability and safety of biologic therapies for plaque psoriasis.

Evaluating IL-23 Inhibitors with Long-Term Data and Real-World Evidence

Roy Beck, MD, PhD, is the founder of the Jaeb Center for Health Research.

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

INHALE-1: Afrezza Safe but Not Superior to Rapid-Acting Analogue in Children, With Roy Beck, MD, PhD

Howard Trachtman, MD, is an adjunct clinical professor of pediatrics at the University of Michigan.

Listen to our conversation with Trachtman about sparsentan's recent FDA approval for FSGS.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

Latest News

Screening Smarter: Identifying MASLD Risk in Women

Asundexian Reduces Stroke Incidence Without Increasing Bleeding, With Ashkan Shoamanesh, MD

Targeting Positive Affect May Prevent Depression Relapse, With Marie-José van Tol, PhD

REZOLVE-AA: 52-Week Data Highlight Positive Alopecia Areata Outcomes with Rezpegaldesleukin

Sustained 1-Year Efficacy Seen with Clascoterone for Androgenetic Alopecia, With Maria Hordinsky, MD